Table VI.
Multivariate analysis of overall survival in PTCL.
| Overall survival | ||
|---|---|---|
| Factor | OR (95% CI) | P-value |
| LDH | ||
| Upper limit of normal vs. normal | 0.574 (0.272–1.211) | 0.145 |
| B2M | ||
| Upper limit of normal vs. normal | 0.631 (0.344–1.159) | 0.138 |
| IPI | ||
| 0–2 vs. 3–5 | 1.170 (0.535–2.559) | 0.694 |
| Ki-67 | ||
| >31% vs. ≤30% | 0.556 (0.273–1.131) | 0.105 |
| Clinical staging | ||
| III–IV vs. I–II | 0.360 (0.148–0.875) | 0.024a |
| Presence of B symptoms | ||
| Present vs. absent | 0.642 (0.342–1.207) | 0.169 |
| Marrow involvement | ||
| Present vs. absent | 0.883 (0.480–1.627) | 0.690 |
| Sex | ||
| Female vs. male | 0.805 (0.450–1.440) | 0.456 |
| Age | ||
| >60 vs. ≤60 | 1.039 (0.560–1.929) | 0.902 |
| Expression of HDAC2 | ||
| Low expression vs. high expression | 0.462 (0.234–0.914) | 0.027a |
a
P<0.05. PTCL, peripheral T cell lymphoma; OR, odds ratio; CI, confidence interval; LDH, lactate dehydrogenase; B2M, β2 microglobulin; IPI, international prognostic index; HDAC2, histone deacetylase 2.